Summary of Financial Report for the 3rd Quarter of FY2024 (Non-Consolidated)

January 31, 2025

Listed Company Name : Japan Tissue Engineering Co., Ltd. https://www.jpte.co.jp
Listed Securities Exchange : Tokyo Growth Stock Code 7774
Representative : Ken-ichiro Hata, President and CEO
Contact : Hiroaki Murai, Corporate Officer TEL (0533) 66-2020

(Rounding down to the nearest million yen)

1. Non-consolidated financial Results for the nine months ended December 31, 2024

(1) Business Results (% indicate increase / decrease on previous fiscal year)

	Net sales		Operating income		Ordinary income		Net income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
3rd quarter of FY2024	1,706	-4.4	-331	—	-330	—	-350	—
3rd quarter of FY2023	1,785	23.7	-51	—	-50	—	-53	—

	Net income per share	Net income per share, diluted
	Yen	yen
3rd quarter of FY2024	-8.62	—
3rd quarter of FY2023	-1.32	—

(2) Financial Condition

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
3rd quarter of FY2024	6,448	5,730	88.9
FY2023	6,988	6,080	87.0

Note: Equity 3rd quarter of FY2024: 5,730 million yen FY2023: 6,080 million yen

2. Cash Dividends

	Dividends per share				
	1Q end	2Q end	3Q end	Term end	Annual
	yen	yen	yen	yen	yen
FY2023	—	0.00	—	0.00	0.00
FY2024	—	0.00	—		
FY2024 (Forecast)				0.00	0.00

Note: Revisions to cash dividends this quarter No

3. Forecast for FY2024 (April 1, 2024 to March 31, 2025)

(% indicate increase/decrease on previous year)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	yen
FY2024	2,500	-0.6	-200	—	-202	—	-223	—	-5.49

Note: Revisions to forecast this quarter Yes

*Disclaimer regarding appropriate use of forecasts and related points of note

The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these materials including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors. This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.

Japan Tissue Engineering Co., Ltd.
Non-consolidated Financial Statements for 3rd Quarter of FY2024
(April 1, 2024 - December 31, 2024)

(1) Non-consolidated Balance Sheets

(Thousands of yen)

	FY2023 As of March 31, 2024	FY2024 3Q As of December 31, 2024
Assets		
Current assets		
Cash and deposits	4,266,344	4,070,671
Notes and accounts receivable - trade	526,295	392,438
Electronically recorded monetary claims - operating	82,362	27,318
Work in process	55,679	23,472
Raw materials and supplies	172,886	186,890
Other	235,711	187,156
Total current assets	5,339,279	4,887,947
Non-current assets		
Property, plant and equipment		
Buildings, net	677,485	625,657
Land	582,770	582,770
Other, net	250,624	233,631
Total property, plant and equipment	1,510,880	1,442,059
Intangible assets	102,527	92,784
Investments and other assets	36,086	25,330
Total non-current assets	1,649,495	1,560,173
Total assets	6,988,774	6,448,121
Liabilities		
Current liabilities		
Accounts payable - trade	19,573	39,970
Electronically recorded obligations - operating	64,014	59,614
Income taxes payable	35,443	36,618
Provision for bonuses	161,792	63,069
Provision for bonuses for directors (and other officers)	—	2,264
Other	592,708	467,396
Total current liabilities	873,531	668,933
Non-current liabilities		
Provision for retirement benefits	—	6,600
Provision for retirement benefits for directors (and other officers)	34,900	42,300
Total non-current liabilities	34,900	48,900
Total liabilities	908,431	717,833
Net assets		
Shareholders' equity		
Share capital	4,958,763	4,958,763
Capital surplus	2,788,763	2,788,763
Retained earnings	−1,666,875	−2,016,927
Treasury shares	−308	−311
Total shareholders' equity	6,080,342	5,730,287
Total net assets	6,080,342	5,730,287
Total liabilities and net assets	6,988,774	6,448,121

(2) Non-consolidated Statements of Income

(Thousands of yen)

	FY2023 3Q Nine months ended December 31, 2023	FY2024 3Q Nine months ended December 31, 2024
Net sales	1,785,633	1,706,416
Cost of sales	606,805	706,414
Gross profit	1,178,827	1,000,001
Selling, general and administrative expenses	1,230,497	1,331,805
Operating loss	−51,669	−331,803
Non-operating income		
Interest and dividend income	587	1,036
Parking Income from employees	705	716
Other	522	564
Total non-operating income	1,815	2,317
Non-operating expenses		
Foreign exchange losses	875	579
Other	0	77
Total non-operating expenses	875	656
Ordinary loss	−50,729	−330,142
Loss before income taxes	−50,729	−330,142
Income taxes - current	2,852	19,909
Total income taxes	2,852	19,909
Loss	−53,581	−350,051

(3) Segment Information

I. FY2023 (April 1, 2023 – December 31, 2023)

(Thousands of yen)

	Reportable segments				Reconciling items	Per quarterly financial statements
	Regenerative Medicine Business	Custom Development and Manufacturing Business	Research and Development Support Business	Reportable segments		
Sales						
Revenues from external customers	973,127	635,384	177,121	1,785,633	—	1,785,633
Transactions with other segments	—	—	—	—	—	—
Net sales	973,127	635,384	177,121	1,785,633	—	1,785,633
Segment profit (loss)	112,363	445,558	63,072	620,993	−672,662	-51,669

II. FY2024 (April 1, 2024 – December 31, 2024)

(Thousands of yen)

	Reportable segments				Reconciling items	Per quarterly financial statements
	Regenerative Medicine Business	Custom Development and Manufacturing Business	Research and Development Support Business	Reportable segments		
Sales						
Revenues from external customers	1,056,264	477,813	172,337	1,706,416	—	1,706,416
Transactions with other segments	—	—	—	—	—	—
Net sales	1,056,264	477,813	172,337	1,706,416	—	1,706,416
Segment profit (loss)	109,539	243,104	48,673	401,317	-733,121	-331,803